{
    "clinical_study": {
        "@rank": "40287", 
        "arm_group": {
            "arm_group_label": "IV iron", 
            "arm_group_type": "Other", 
            "description": "Intravaneous iron(1000 mg low molecular weight iron dextran over 60 minutes) for moderate to severe iron deficient anemia of pregnancy in women intolerant of or unresponsive to oral iron."
        }, 
        "brief_summary": {
            "textblock": "To determine the percentage of women who achieve anemia correction after a single dose of\n      1000mg of low molecular weight iron dextran(infed)."
        }, 
        "brief_title": "Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pregnancy", 
        "detailed_description": {
            "textblock": "To determine the percentage of women who achieve anemia correction after a single dose of\n      1000mg of low molecular weight iron dextran(infed).\n\n      To determine whether IV iron supplementation has a higher satisfaction with treatment as\n      compared to oral supplementation in a population previously intolerant of or unresponsive to\n      oral iron.\n\n      To evaluate the safety of IV low molecular weight iron dextran in pregnant women.\n\n      To assess maternal and fetal outcomes-preterm delivery, low birth weight deliveries, ER\n      visits and hospitalizations related to preterm labor, preterm contractions, ante-partum and\n      post-partum transfusions, maternal hemoglobin at post-partum visit after IV iron\n      supplementation groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  pregnant women intolerable to oral iron. hbg <10.9 g/dl during second or third\n             trimester.\n\n        Exclusion Criteria:\n\n          -  known sensitivity to IV iron. hemoglobinopathies. hemolytic anemia. women who have\n             received or will receive blood transfusions. women with significant vaginal\n             bleeding(>200 cc blood loss)prior to delivery. women with documented history of\n             allergy to more than one class of drug clinically significant anemia requiring\n             therapy in the opinion of the obstetrician, in the first trimester."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038023", 
            "org_study_id": "Intravaneous Iron in Pregnancy", 
            "secondary_id": "Infed"
        }, 
        "intervention": {
            "arm_group_label": "IV iron", 
            "description": "1000 mg of Iron dextran administered over one hour", 
            "intervention_name": "Intravaneous iron(low molecular weight iron dextran)", 
            "intervention_type": "Drug", 
            "other_name": "Iron Dextran(InFed)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dextrans", 
                "Iron-Dextran Complex", 
                "Iron"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Iv iron in pregnant women", 
            "second and third trimester"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "location": {
            "contact": {
                "email": "mauerbachmd@abhemonc.com", 
                "last_name": "Michael Auerbach, MD", 
                "phone": "410-780-4050"
            }, 
            "contact_backup": {
                "email": "srineerrn@yahoo.com", 
                "last_name": "Stella Rineer, RN", 
                "phone": "410-780-4050"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21237"
                }, 
                "name": "Auerbach Hematology Oncology Assoc"
            }, 
            "investigator": {
                "last_name": "Michael Auerbach, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Moderate to Severe Iron Deficient Anemia of Pregnancy in Women Intolerant of or Responsive to Oral Iron.", 
        "other_outcome": {
            "description": "To evaluate the safety of IV low molecular weight iron dextran in pregnant women. Also to asses maternal and fetal outcomes-preterm delivery, low-birth weight deliveries, ER visits and hospitalizations related to preterm labor, preterm contractions, ante-partum and post partum transfusions, maternal hemoglobin at post-partum visit after IV iron supplementation groups.  A questionaire with a list of symptoms to include nausea, dizziness, hypotension, edema, headache, abdominal pain, chest pain, cough, itching, fever, back pain, muscle cramps and rash are asked immediately after administration and phone calls at 24, 48 hours and 7 days.", 
            "measure": "safety as measured by number of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks after infusion and 4 weeks post-partum"
        }, 
        "overall_contact": {
            "email": "mauerbachmd@abhemonc.com", 
            "last_name": "Michael Auerbach, MD", 
            "phone": "410-780-4050"
        }, 
        "overall_contact_backup": {
            "email": "srineerrn@yahoo.com", 
            "last_name": "Stella Rineer, RN", 
            "phone": "410-780-4050"
        }, 
        "overall_official": {
            "affiliation": "Auerbach Hematology Oncology", 
            "last_name": "Michael Auerbach, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "percentage of women who achieve anemia correction after a single dose of 1000mg of low molecular weight iron dextran(INfeD).", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks after infusion and 4 weeks post-partum"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038023"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Auerbach Hematology Oncology Associates P C", 
        "sponsors": {
            "collaborator": {
                "agency": "Pharmacosmos A/S", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Auerbach Hematology Oncology Associates P C", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}